Clinical Trial Update: Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating panobinostat in patients with relapsed and bortezomib-refractory multiple myeloma; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Panobinostat (Panobinostat)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Relapsed and Bortezomib Refractory Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2015-03-27